ArticleTransplantation and cellular therapy2026
Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
High-dose post-transplant cyclophosphamide (PTCy) for graft versus host disease (GVHD) prophylaxis after HLA-matched allogeneic hematopoietic cell transplantation (HCT) in adults with hematologic malignancies is standard of care when combined with tacrolimus and mycophenolate mofetil (MMF) after reduced intensity conditioning (RIC). However, use of PTCy after HLA-matched HCT in pediatrics is not well described. To show that PTCy allows for successful engraftment, survival, and low rates of GVHD, a retrospective analysis of patients ≤21 years treated at Johns Hopkins (n = 22) who underwent HLA-matched related (MSD, 73%) or unrelated HCT (MUD, 27%) between 2013 and 2023 was performed. GVHD prophylaxis included PTCy alone (n = 15) or a priori with tacrolimus and MMF for peripheral blood stem cell grafts (n = 5) and/or RIC (Flu/Cy/200cGy TBI, n = 4). Median patient age was 16.5 years and diagnoses included AML [CR1 = 4, CR≥2 = 4; minimal residual disease (MRD) = 2], ALL [CR1 = 4, CR≥2 = 6; MRD = 2], and MDS [1 treated, 3 untreated]. Evaluable patients had full donor chimerism at day +60. Median time to neutrophil and platelet recovery was 18 and 19.5 days. Two developed acute GVHD (aGVHD) Gr IV after myeloablative MUD bone marrow HCT with PTCy alone and both died; no chronic GVHD (cGVHD). Cumulative incidence of relapse at 3y was 48%, 38% for MRD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.